RT Journal Article
SR Electronic
T1 Amphiregulin Is a Prognostic Factor in Colorectal Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2315
OP 2321
VO 32
IS 6
A1 OHCHI, TAKAFUMI
A1 AKAGI, YOSHITO
A1 KINUGASA, TETSUSHI
A1 KAKUMA, TATSUYUKI
A1 KAWAHARA, AKIHIRO
A1 SASATOMI, TERUO
A1 GOTANDA, YUKITO
A1 YAMAGUCHI, KEIZO
A1 TANAKA, NATSUKI
A1 ISHIBASHI, YOSHIAKI
A1 MIYAMOTO, SHINGO
A1 KAGE, MASAYOSHI
A1 SHIROUZU, KAZUO
YR 2012
UL http://ar.iiarjournals.org/content/32/6/2315.abstract
AB Amphiregulin is an epidermal growth factor (EGF) which is a ligand of epidermal growth factor receptor (EGFR). Amphiregulin is the most enhanced EGFR ligand in colon cancer. Here we report on the expression of Amphiregulin using immunohistochemical staining in primary colorectal cancer, and the correlations between prognosis and various clinicopathological factors. We examined 174 consecutive patients who underwent curative resection of colorectal cancer, from January 2002 to December 2004. Amphiregulin was positive in 156 (90%) patients. Amphiregulin was found to be an independent predictor of overall survival [hazard ratio=6.25 (95% confidence interval=1.3-111.5; p=0.0144)] and relapse-free survival [hazard ratio=6.94 (95% confidence interval=1.5-123.2; p=0.0075)]. We conclude that the expression of Amphiregulin in a primary colorectal tumor is useful as an indicator of prognosis and as a predictor of recurrence.